Buspirone: What is it all about?

@article{Loane2012BuspironeWI,
  title={Buspirone: What is it all about?},
  author={Clare Loane and Marios Politis},
  journal={Brain Research},
  year={2012},
  volume={1461},
  pages={111-118}
}
Buspirone is an anxiolytic drug and is a partial agonist for the serotonin 5-HT(1A) receptors as well as possessing low affinity and is an antagonist for the dopamine D(2) autoreceptors, with some evidence of a weak affinity to 5-HT(2) receptors. The underlying mechanism of action of buspirone is not clear; however it is thought that its main pharmacology is mediated via the 5-HT(1A) receptors. Initially developed for use in the treatment of generalised anxiety disorder, it appears that… Expand
Vilazodone for the Treatment of Depression: An Update
TLDR
Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile and 2 RCTs recently documented the efficacy and safety of vilazdone in patients with generalized anxiety disorder, which could be a start of broadening vilazodones usage or FDA approval in diverse anxiety disorders. Expand
Behavioral effects of buspirone in a mouse model of posttraumatic stress disorder
TLDR
Positive effects of buspirone are suggested in the treatment of selected PTSD-like symptoms and prompt for its further clinical evaluation. Expand
Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience
TLDR
The present finding demonstrates that buspirone exerts inhibitory effects on psilocybin-induced effects, presumably via 5-HT1A receptor activation, an interaction between 5- HT1A and5-HT2A receptors, or both. Expand
Therapeutic doses of buspirone block D3 receptors in the living primate brain.
TLDR
For oral buspirone to achieve greater than 80% sustained D3R occupancy, as might be needed to treat addiction, higher doses than those used to treat anxiety (maximal 60 mg) will be required. Expand
Nucleus incertus contributes to an anxiogenic effect of buspirone in rats: Involvement of 5-HT1A receptors
TLDR
5-HT1A receptors in the NI contribute to the anxiogenic effect of an acute high dose of buspirone in rats and may be functionally relevant to physiological anxiety. Expand
Safety and Tolerability of Anxiolytics/Sedative-Hypnotics
TLDR
Emerging evidence indicates that pregabalin, a pharmacological agent approved for the treatment of generalized anxiety disorder, also has the potential to lead to abuse and dependence, and is still valuable in the management of anxiety disorders and transient insomnia. Expand
Levo-Tetrahydroberberrubine Produces Anxiolytic-Like Effects in Mice through the 5-HT1A Receptor
TLDR
The results suggest that l-THBr may produce potent anxiolytic-like effects mainly through serotonin receptors. Expand
Expression of serotonin 1A and 2A receptors in molecular- and projection-defined neurons of the mouse insular cortex
TLDR
A molecular and neuroanatomical map of the 5-HT system within the insular cortex is defined, providing ground knowledge to identify the potential role of serotonergic modulation of selective insular populations in anxiety. Expand
Studies of the Effects of a Complex of Buspirone with Glycyrrhyzic Acid on the Behavior of Mice during Formation of an Anxious-Depressive State
TLDR
The possible mechanisms of action of these compounds on the background of changes in the sensitivity of brain 5-HT1A receptors due to the formation of the pathological state in mice due to social stress are discussed. Expand
The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats.
TLDR
The results suggest that AP521 exhibits potent anxiolytic effects by acting as a postsynaptic 5-HT1A receptor agonist and by enhancing serotonergic neural transmission in the mPFC by a novel mechanism of action. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 88 REFERENCES
Molecular basis of buspirone's anxiolytic action.
TLDR
Even though buspirone and the benzodiazepines do not obviously share a common mode of action, the possibility is discussed that there is an underlying common mechanism of responsible for their antianxiety effects. Expand
Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.
TLDR
Although only wider clinical use for longer periods of time will more clearly define some elements of its pharmacological profile, with its low incidence of sedation buspirone is a useful addition to the treatments available for generalised anxiety. Expand
Buspirone, Parkinson's disease, and the locus ceruleus.
TLDR
Clinical observations support the concept that central noradrenergic stimulation can adversely affect parkinsonian symptoms. Expand
Attenuation of apomorphine-induced sensitization by buspirone
TLDR
It is suggested that buspirone may oppose the development of sensitization to apomorphine by decreasing the sensitivity of somatodendritic 5-HT(1A) receptors. Expand
Dopamine receptor antagonism by the novel antianxiety drug, buspirone
TLDR
The data suggest that buspirone enhances DA neuronal activity, in part, by weakly inhibiting presynaptic DA receptors, and that the drug has minimal effects on postsynapticDA receptors. Expand
Pharmacology and neurochemistry of buspirone.
TLDR
Buspirone appears to interact only with the dopaminergic system and possesses properties that are similar to both dopamine agonists and dopamine antagonists. Expand
Neuropharmacology of buspirone.
Buspirone is a clinically effective anxiolytic with a unique structure and pharmacology which distinguishes it from the benzodiazepines. It has been termed anxioselective because it lacksExpand
Hormonal response to buspirone is not impaired in major depression
TLDR
The hypothesis of an altered postsynaptic 5‐HT1A receptor function in major depression is not supported and results indicate no consistent changes in the hormonal response to the 5‐ HT1A agonist buspirone in depressed patients. Expand
Drug therapies for tardive dyskinesia: part 2.
  • R. Howland
  • Medicine
  • Journal of psychosocial nursing and mental health services
  • 2011
TLDR
Tardive dyskinesia (TD) is a serious complication associated with the long-term use of dopamine receptor-blocking drugs, and a number of drugs appear to have some benefit for its treatment. Expand
Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of α2-adrenergic receptors underlie its actions
The serotonin1A receptor partial agonist, buspirone, also displays antagonist properties at D2 receptors and is metabolized to the alpha2-adrenergic receptor antagonist, 1-(2-pyrimidinyl-piperazine).Expand
...
1
2
3
4
5
...